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Circulating Antimicrobial Peptide LL-37 Status in Type 1 
Diabetes Mellitus and its Relation with Glycemic Control
Antimicrobial-peptides are important molecules of constitutive innate immunity. Though patients with 
diabetes mellitus are generally prone to infections, there is limited information on their antimicrobial-
peptide status. We assessed the circulating LL-37 antimicrobial peptide (also referred as cathelicidin) 
levels in patients with type 1 diabetes mellitus and its relation with their glycemic status. The LL-37 
mRNA expression was assessed in the peripheral blood mononuclear cells (PBMC) by quantitative RT-
PCR using ß-actin and cytochrome-C1 as the reference genes in 154 subjects (Type 1 diabetes, n=111 
and healthy subjects, n=43).  Serum LL-37 was quantiﬁed using sandwich-ELISA. Average HbA1c 
over last 2 years and current HbA1c were used to determine long-term and short-term glycemic status. 
LL-37 mRNA expression and serum LL-37 levels were correlated with the glycemic status. The LL-37 
mRNA copies were comparable between type 1 diabetes and healthy subjects [median (IQR) = 6.7 
(1.8–15.28) vs. 7.2 (2.23–21.86), respectively, P = 0.42]. There was no signiﬁcant difference in serum 
LL-37 levels between the two groups [median (IQR) = 3.9 (2.88–7.52) vs. 5.0 (3.19–9.05) ng/ml, 
respectively, P = 0.52]. The LL-37 mRNA and its protein concentration showed no signiﬁcant 
correlation with the average or current HbA1c values. The constitutive circulating antimicrobial 
peptide LL-37 status is not signiﬁcantly altered in patients with type 1 diabetes mellitus and also not 
affected by their glycemic status.
Keywords: Innate-immunity, diabetes mellitus, antimicrobial peptide LL-37, cathelicidin, 
glycosylated hemoglobin.
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ABSTRACT
Introduction 
 Recurrent bacterial and fungal infections 
of genitourinary tract, skin, and lungs are 
common in patients with type 1 diabetes mellitus 
(T1DM) (1-3). The reasons of increased 
susceptibility to infections in diabetes are not 
clear but could involve hyperglycemia mediated 
abnormalities in innate immunity involving 
polymorphonuclear cell dysfunction and various 
antimicrobial peptides (4-5).  The LL-37 
antimicrobial peptide (cathelicidin) is an 
essential component of the innate immunity. It is 
produced by several cells such as leukocytes, 
keratinocytes and mucosal epithelial cells to 
promote phagocytosis in macrophages, dendritic 
cell differentiation, chemokine production, 
keratinocyte migration and wound healing. LL-
37 also inhibits apoptosis of leukocytes and 
bioﬁlm formation (6-9).
 Though there is increasing interest in the 
role of LL-37 in bacterial infections, HIV and 
tuberculosis, the information on LL-37 
expression in diabetes is limited. Since patients 
with uncontrolled diabetes may be particularly 
prone to infections, LL-37 expression might be 
altered in them (10-13). Earlier studies involving 
limited number of patients showed variable 
status of LL-37 in diabetes. Gonzales et al and 
Santiago et al reported reduced LL-37 mRNA 
expression in circulating leukocytes in DM and 
peri-ulcer skin biopsy of patients with diabetic 
foot, respectively (11, 12) and Brauner et al 
showed reduced LL-37 levels in T1DM as 
compared to patients with type 2 diabetes (13). 
The relationship of glycemic control with 
circulating LL-37 has not been studied till date. 
Present study investigated LL-37 mRNA 
expression in peripheral blood mononuclear 
cells (PBMC) and serum LL-37 concentration in 
a cohort of 111 patients with T1DM and assessed 
its relation with their glycemic status.
Materials and Methods 
 The study included 111 patients with 
T1DM attending 'Diabetes of young' clinic at the 
All India Institute of Medical Sciences, Delhi.  
Pregnant, lactating women and patients with 
overt bacterial infections were excluded. Their 
details including age at onset of diabetes, 
nephropa thy,  r e t inopa thy,  pu lmonary 
tuberculosis and serial HbA1c values during 
previous two years were noted from clinical 
records. Forty three healthy subjects with 
normal HbA1c who consented for the study were 
included for comparison. 
Quantitative Real Time Reverse Transcription 
PCR (qRT-PCR) for LL-37 mRNA Expression 
 Ten ml blood was collected in fasting state 
in nuclease-free heparinized tube for isolating 
PBMC by Ficol and RNA extraction using Trizol 
(Invitrogen, Carlsbad) (14). RNA was quantiﬁed 
using UV spectrophotometer (GeneQuant, 
Amersham) and its quality was assessed by 
agarose gel electrophoresis and RNA integrity 
n u m b e r  ( B i o - a n a l y s e r  2 1 0 0 ,  A g i l e n t 
Technologies Inc.). First strand of cDNA was 
prepared using 2.0µg of total RNA, random 
hexamer nucleotides and M-MuLv reverse 
transcriptase in 20µl reaction incubated at 25˚C 
for 10 min followed by 42˚C for 1 hour (14).
 The qRT-PCR for LL-37 mRNA was 
carried out using SYBR-mix (Biorad, Hercules, 
USA) in CFX96 cycler (Bio-Rad) in 20µl 
reaction using LL-37 gene-speciﬁc primers 
(sense-5'gcggtggtcactggtgctcctgctgct3' and 
antisense-5'gaagaaatcacccagcagggcaaatc3') 
(14). The RNA expression of housekeeping-
genes (ß-actin and cytochrome C1) was used as 
control. The sense and antisense primers for ß-
ac t in  (5 ' ca tg tacg t tgc ta tccaggc3 '  and 
5'ctccttatgtcacgccacgat3') and cytochrome C1 
( 5 ' a g c t g c c a a c a a c g g a g c a t 3 '  a n d 
5'gactgaccacttgtgccgct3') were designed using 
' P r i m e r - 3 - s o f t w a r e ' 
(http://www.ncbi.nlm.nih.gov/tools/primer-
blast).  The PCR conditions were 94°C  x 3 min, 
39 cycles of 94°C x 30s, 55°C  for ß-actin and  
60°C  for  LL-37 and cytochrome C1 each x 30s, 
72°C x 30s , 86°C x 20s, ﬁnal extension 72°C x 
10 min.  The intra-assay and inter-assay 
variation were 0.9-1.7% and was 3-5%, 
respectively.  All the reactions were performed 
in duplicates, and speciﬁcity of ampliﬁed 
products was checked by post-PCR melt-curve 
analysis and agarose gel electrophoresis (Fig.1). 
The speciﬁcity of ampliﬁed products of LL-37 
was checked by DNA sequencing and that of ß-
actin and cytochrome C1 by RFLP using 
Eco0109I and TaqI restriction enzymes, 
respectively.  The mRNA copy number of LL-37 
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was determined per 10  copies of geometric 
mean of ß-actin and cytochrome C1.
ELISA for Serum LL-37 Concentrations
 A sandwich ELISA with LL-37 speciﬁc 
antibody precoated on to 96 well microplate was 
used (MyBiosource Inc., USA). Brieﬂy, blood 
was allowed to clot at room temperature, 
centrifuged at 1000xg for 15 minutes at 4°C and 
serum was stored at -80°C.  Assay was carried 
out using 100 µl of serum along with seven 
standards ranging from 1.56-100 ng/ml.  Avidin-
HRP was used in conjunction with biotinylated 
detection antibodies as second step reagent for 
indirect enzymatic labeling. Serum samples 
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from patients and healthy subjects were put in 
the ELISA plates in 2:1 ratio to minimize assay-
related variation.  The ELISA was carried out as 
per the kit protocol with optical density 
measured at a wavelength of 450 nm using i-
Mark reader (Biorad).  The speciﬁc absorbance 
was plotted by four-parameter logistic curve 
ﬁtting.  The assay had minimum detection limit 
of 0.94 ng/ml of natural and recombinant LL-37, 
coefﬁcient of variation < 10% and reportable 
range between 1.56-100.0 ng/ml.
 The  s tudy  was  app roved  by  the 
Institutional Ethics Committee of All India 
Institute of Medical Sciences, New Delhi.  
Written informed consent was obtained from all 
subjects.
Statistical Analysis
 Data are shown as mean ± SD, frequencies 
and median with interquartile range. The 
differences in the study parameter between 
patients with diabetes and healthy subjects were 
compared using Student's 't' test or by Mann' 
Whitney 'U' test as appropriate. Differences in 
the frequency of subject with serum LL-37 value 
below the detection range of the assay (<1.56 
ng/ml) between diabetes and controls were 
analyzed using chi Square test.  Pearson's 
correlation coefﬁcient was used to assess 
relationship between LL-37 mRNA expression 
with average HbA1c over last two years and 
current HbA1c. Similar analysis was also carried 
out for serum LL-37. All the statistical analyses 
were implemented on SPSS 11.5 (SPSS Inc., 
USA). A two-tailed P value of < 0.05 was 
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Fig.1: Agarose gel (1.5%) electrophoresis showing the PCR products of ß-actin, CYC1 and LL-37 
(lanes 2,3,4, respectively), Lane 1: 100 bp DNA ladder (A); LL-37 expression in T1DM and 
3
controls, mRNA copies/10  reference genes (B) and  serum LL-37 concentration (C) 
Parameter 
 
Diabetes
 
(n=111)
 Healthy subjects
 
(n=43)
 t
 
and U-
values
 P
Age (years)
 
28.6 ± 11.68
 
29.6 ± 5.86
 
U= 2152.0
 
0.35  
Male: Female (n)
 
56:55
 
23:20
 
-
 
0.86  
Body mass index (kg/m
2
)
 
20.6 ± 4.00
 
25.1 ± 2.79
 
U = 803
 
<0.001
 
HbA1c (mmol/mol) 77.1 ± 21.78  35.1 ± 3.62  U = 1.0  <0.001
 
Total leukocytes (count/mm
3
) 7462 ± 1920  7039  ± 2041  t =  1.2  0.24
 
Polymorphs (%) 59.1 ± 9.71  58.7  ± 6.05  U  =  1051  0.98
 
Lymphocyte (%)
 
30.4
 
± 8.47
 
29.9 ± 4.14
 
U
 
=
 
1014
 
0.79
 
Erythrocyte sedimentation rate (mm/hr)
 
17.6 ± 13.36
 
15.7 ± 9.3
 
U = 2333
 
0.90
 LL-37 mRNA/10
3 
housekeeping copies
 Median (IQR)
 
6.7 (1.8 –
 
15.28)
 
7.2 (2.23 –
 
21.86)
 
U = 2186
 
0.42
Serum LL-37 (ng/ml) Median (IQR)
 
3.9 (2.88–7.52)
 (n = 60)
5.0 (3.19–9.05)
 (n= 27)
U = 740.5
 
0.52
considered signiﬁcant.
Results
 Table 1 shows the clinical and biochemical 
characteristics of the study subjects.  The mean 
age and male: female ratio of patients (28.6 ± 
11.68 years and 56:55) and healthy subjects 
(29.6 ± 5.86 years and 23:20) were comparable. 
The mean BMI was signiﬁcantly less in the 
diabetes group than healthy subjects (20.6 ± 4.0 
2 2
kg/m  and 25.1 ± 2.79 kg/m , respectively, P 
<0.001). The mean HbA1c was higher in 
diabetes than healthy subjects [9.2 ± 1.98% (77.1 
± 21.78 mmol/mol) and 5.4±0.33% (35.1 ± 3.62 
mmol/mol), P <0.001]. The mean duration of 
diabetes was 15.4 ± 9.12 years and history of 
diabetic ketoacidosis was present in 76 (68%) 
patients.  GAD  auto-antibodies were positive 
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in 58.6% of the 87 patients tested. Retinopathy 
and proteinuria >150 mg/24 hours were present 
in 22.5% and 5.4%, respectively. The mean 
hemoglobin and leukocyte counts were in 
normal range in both patients and healthy 
subjects.
LL-37 mRNA Expression and its Serum 
Concentration in Diabetes  
 The mean LL-37 mRNA expression was 
comparable between diabetes and healthy 
groups. In view of the skewed distribution of LL-
37 mRNA expression, the two groups were 
compared using non-parametric test. There was 
no difference in the median copy number of LL-
37 mRNA) between the two groups (Table 1).  
The median serum LL-37 protein concentration 
were comparable between diabetes and healthy 
subjects [median (IQR) = 3.9 (2.88–7.52) vs. 5.0 
(3.19–9.05) ng/ml, respectively, P = 0.52]. 
Similarly, the frequency of subjects with serum 
LL-37 below the detection range were 
comparable between diabetes and control 
groups (45.9% vs. 37.2%, respectively,              
P = 0.42).  
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Table 1: Clinical and biochemical characteristics of study subjects
Correlation of LL-37 mRNA Expression and 
Serum LL-37 Protein with Glycemic Status
 The LL-37 mRNA expression showed no 
signiﬁcant correlation with the current HbA1c  
(r = -0.014, P = 0.88) and the average HbA1c 
during previous two years (r = 0.105, P = 0.27). 
Similarly, there was lack of signiﬁcant 
correla t ion between the serum LL-37 
concentration and current HbA1c (r = 0.05, P = 
0.72) and average HbA1c (r = 0.03, P = 0.83). 
 Eleven of 111 T1DM patients had M.tb 
positive sputum culture. The LL-37 mRNA 
expression and its serum concentration showed 
no signiﬁcant differences between patients with 
and without sputum culture positive for M.tb.
Discussion
 The reasons of susceptibility to infections 
in patients with diabetes and their relation to 
hyperglycemia are under investigation (7-9, 15-
17). Antimicrobial peptides are a key component 
of the ﬁrst and second layer of defense of the 
body. Its presence in the skin and mucosal 
epithelial barrier supplement the ﬁrst layer of 
defense. Polymorphonuclear cells secreting LL-
37 pass through various compartments of the 
body to provide defense against various 
pathogenic organisms (9, 18). Recently, there 
has been interest in the altered expression of 
circulating LL-37 in diabetes (11, 13). However, 
results have been variable, which could be due to 
the limited number of subjects in these studies 
(11, 13). The present study has been carried out 
to assess possible alteration in the LL-37 
expression among patients with diabetes. The 
strength of the study are a large cohort of patients 
with T1DM, age matched healthy subjects, 
measurement of both mRNA expression and 
serum LL-37 concentration and the availability 
of HbA1c data of patients during previous two 
years.
 The present study showed no signiﬁcant 
alteration in the LL-37 mRNA expression and 
circulating LL-37 protein concentration in 
patients with diabetes. Interestingly, both LL-37 
mRNA and LL-37 protein concentration also 
showed no signiﬁcant relationship with current 
or average HbA1c indicating that circulating 
LL-37 expression is not altered with severity of 
hyperglycemia. There have been only two 
previous studies reporting mRNA expression in 
the PBMC and serum concentration of LL-37 in 
patients with diabetes. Gonzalez et al reported 
signiﬁcantly lower mRNA expression of LL-37 
in 30 patients with T2DM compared to healthy 
subjects (P <0.001) (11).  Brauner et al assessed 
the serum concentration of LL-37 in 58 patients 
with diabetes (27 T1DM and 31 T2DM) and 19 
healthy subjects (13). The study revealed 
signiﬁcantly lower serum LL-37 concentration 
T1DM compared to those with T2DM. 
However, the LL-37 levels among patients with 
T1DM were comparable to the control group. 
Interestingly, in the current study we did not ﬁnd 
any signiﬁcant difference in LL-37 expression 
between patients with and without sputum M.tb 
positivity.  These preliminary ﬁndings need to be 
further assessed in future studies targeting larger 
cohort of diabetes patients with and without 
active tuberculosis.
 Thus, the lack of signiﬁcant difference in 
the serum LL-37 concentration between patients 
and healthy subjects in current study coupled 
with no signiﬁcant relationship of LL-37 with 
glycemic control suggest that constitutive LL-37 
expression is not altered in patients with diabetes 
at least in the circulation. Further, the expression 
of LL-37 peptide is not affected by adverse 
glycemic status in patients with T1DM. 
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